Skip to Content

Lomustine Pregnancy and Breastfeeding Warnings

Lomustine is also known as: CCNSB Capsules, CeeNU, Gleostine

Lomustine Pregnancy Warnings

Animal studies have revealed evidence of embryotoxicity and teratogenicity at dose levels equivalent to the human dose; and fertility impairment in males at doses somewhat higher than the human dose. This drug should be regarded as a potential mutagen. There are no controlled data in human pregnancy. AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

UK: Use of this drug is contraindicated in pregnant patients. US: Use should be avoided during pregnancy as this drug can cause fetal harm based on animal studies. AU: Use should be avoided during pregnancy unless the expected benefit outweighs any potential risk. AU TGA pregnancy category: D US FDA pregnancy category: D Comments: -Female patients of childbearing potential should be advised to avoid becoming pregnant while taking this drug, and should be apprised of the potential hazard to the fetus if pregnancy occurs during treatment. -All patients should be advised to use effective contraception during treatment and for 6 months after therapy. (UK) -Male patients should be informed about the possibility of irreversible infertility caused by this drug; advised not to father children during treatment and for 6 months after treatment cessation; and to seek advice regarding sperm conservation prior to treatment initiation. (UK)

See references

Lomustine Breastfeeding Warnings

UK: Use of this drug is contraindicated in breastfeeding mothers. AU, US: This drug should not be given to nursing mothers. Excreted into human milk: Yes Comments: Some metabolites are excreted in breast milk and may be harmful in young children.

See references

References for pregnancy information

  1. "Product Information. Gleostine (lomustine)." NextSource Biotechnology, LLC, Miami, FL.

References for breastfeeding information

  1. "Product Information. Gleostine (lomustine)." NextSource Biotechnology, LLC, Miami, FL.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.